Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026)

Argenx Se (ARGX) posted Income from Continuing Operations of 498000000.0 for Q1 2026, up 23.48% on a QoQ basis from 403294000.0 in Q4 2025, and up 111.59% year-over-year from 235361000.0 in Q1 2025.

Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026) Analysis & Trends

Argenx Se's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 498000000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 111.59% year-over-year to 498000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1574246000.0 (up 301.35% YoY) and the FY2025 annual result came in at 1292035000.0, up 55.1% from the prior year.
  • Income from Continuing Operations was 498000000.0 for Q1 2026 at Argenx Se, up from 403294000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 498000000.0 in Q1 2026 and bottomed at 674167000.0 in Q2 2022.
  • A 5-year average of 109000058.82 and a median of 83851000.0 in 2024 frame the typical range for Income from Continuing Operations.
  • Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 730.63% — and 2025, when it soared 2012.28%.
  • Argenx Se's Income from Continuing Operations stood at 41238000.0 in 2022, then soared by 48.35% to 61178000.0 in 2023, then soared by 37.06% to 83851000.0 in 2024, then surged by 380.97% to 403294000.0 in 2025, then climbed by 23.48% to 498000000.0 in 2026.
  • Business Quant data shows ARGX's Income from Continuing Operations at 498000000.0 in Q1 2026, 403294000.0 in Q4 2025, and 386053000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -37.09 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -26.94 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 498.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 205.99 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 498.00 Mn
Dec 31, 2025 403.29 Mn
Sep 30, 2025 386.05 Mn
Jun 30, 2025 286.90 Mn
Mar 31, 2025 235.36 Mn
Dec 31, 2024 83.85 Mn
Sep 30, 2024 88.02 Mn
Jun 30, 2024 -15.00 Mn
Mar 31, 2024 -74.35 Mn
Dec 31, 2023 61.18 Mn
Sep 30, 2023 83.28 Mn
Jun 30, 2023 -83.86 Mn
Mar 31, 2023 76.18 Mn
Dec 31, 2022 41.24 Mn
Sep 30, 2022 241.02 Mn
Jun 30, 2022 -674.17 Mn
Mar 31, 2022 216.00 Mn
Dec 31, 2021 -244.88 Mn
Sep 30, 2021 230.87 Mn
Jun 30, 2021 106.90 Mn